Retinal-acetylhydrazon | 69460-76-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: Retinal-acetylhydrazon
• 英文别名: Retinal acetylhydrazone；N-[(E)-[(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenylidene]amino]acetamide
• CAS: 69460-76-0
• 化学式: C₂₂H₃₂N₂O
• 分子量: 340.509
• InChiKey: GBJNKYSKQNNZCA-CHUPNPQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Retinoid receptor compositions and methods
  申请人：THE SALK INSTITUTE FOR BIOLOGICAL STUDIES

  公开号：EP0999271A2

  公开（公告）日：2000-05-10

  The present invention relates to novel receptor polypeptides, which, upon interaction with certain ligands, or activation by certain compounds, modulate transcription of certain genes by binding to cognate response elements associated with promoters of such genes. The novel receptors of the invention modulate transcription in the presence of retinoid compounds. The receptors of the present invention differ significantly from known retinoid acid receptors, in protein primar yseqence and in responsiveness to exposure to various retinoids. The invention provides DNAs encoding the novel receptors, expression vectors for expression of the receptors, cells transformed with such expression vectors, cells co-transformed with such expression vectors and with reporter vectors to monitor modulation of transcription by the receptors, and methods of using such co-transformed cells in screening for compounds which are capable, directly or indirectly, of activating the receptors. The invention also provides nucleic acid probes for identifying DNAs which encode additional retinoid receptors of the same class as the novel receptors disclosed herein.

  本发明涉及新型受体多肽，它们在与某些配体相互作用或被某些化合物激活后，通过与与这些基因启动子相关的同源反应元件结合，调节某些基因的转录。本发明的新型受体可在视黄醇化合物存在的情况下调节转录。本发明的受体与已知的视黄酸受体在蛋白质序列和对各种视黄酸的反应性方面有很大不同。本发明提供了编码新型受体的 DNA、表达受体的表达载体、用这种表达载体转化的细胞、用这种表达载体和报告载体共同转化的细胞以监测受体对转录的调节，以及用这种共同转化的细胞筛选能直接或间接激活受体的化合物的方法。本发明还提供了用于鉴定 DNA 的核酸探针，这些 DNA 编码与本发明公开的新型受体属于同一类的其他视黄醇受体。
• Methods for treatment of adenoid cystic carcinoma
  申请人：THE CHILDREN'S MEDICAL CENTER CORPORATION

  公开号：US10668039B2

  公开（公告）日：2020-06-02

  The present invention is directed to compositions and methods for treating Adenoid Cystic Carcinoma (ACC).

  本发明涉及治疗腺样囊性癌（ACC）的组合物和方法。
• Treatment of hyperproliferative diseases
  申请人：——

  公开号：US20030119715A1

  公开（公告）日：2003-06-26

  We describe methods and compositions for treating a patient suffering from a hyperproliferative disorder or photoageing. Our methods involve blocking the activity of a retinol binding protein receptor (RBPr) in cells of the patient, and/or administering to the patient an antagonist of a retinol binding protein receptor (RBPr) and/or lowering the endogenous level of retinoic acid (RA) in cells of said patient.

  我们描述了治疗过度增殖症或光老化患者的方法和组合物。我们的方法包括阻断患者细胞中视黄醇结合蛋白受体（RBPr）的活性，和/或向患者施用视黄醇结合蛋白受体（RBPr）的拮抗剂，和/或降低患者细胞中视黄酸（RA）的内源性水平。
• RETINOID RECEPTOR COMPOSITIONS AND METHODS
  申请人：THE SALK INSTITUTE FOR BIOLOGICAL STUDIES

  公开号：EP0514488A1

  公开（公告）日：1992-11-25
• EP0514488A4
  申请人：——

  公开号：EP0514488A4

  公开（公告）日：1993-02-17